A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

hemolytic disease of the fetus and newborn, m281, hdfn, rhesus disease, hemolytic disease due to fetomaternal alloimmunization, hemolytic disease of the newborn with kell alloimmunization, rhesus (rh) isoimmunization of foetus or newborn, isoimmunization due to other red cell factors, abo isoimmunization of foetus or newborn, haemolytic anaemia due to other unclassified antibodies, isoimmune, isoimmunized